The prognostic value of the serum ferritin in a southern brazilian cohort of patients with Gaucher disease

• Autor(a) principal: Koppe, Tiago de Bone
• Data de Publicação: 2016
• Outros Autores: Moneda, Divair, Siebert, Marina, Paskulin, Lívia D'Avila, Camargo, Matheus Brunstein, Tirelli, Kristiane Michelin, Vairo, Filippo Pinto e, Daudt, Liane Esteves, Schwartz, Ida Vanessa Doederlein
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UFRGS
• Texto Completo: http://hdl.handle.net/10183/150137
• topic: Ferritina; Biomarcadores; Doença de Gaucher; Metabolismo : Ferro; Ferritin; Biomarkers; Gaucher disease; Iron metabolism

The clinical utility of serum ferritin as a biomarker of disease severity and prognosis in Gaucher disease (GD) is still debated. Here, we aimed to evaluate ferritin and its relation to clinicolaboratory parameters of GD patients seen at the Reference Center for Gaucher Disease of Rio Grande do Sul, Brazil, so as to gather evidence on the utility of ferritin as a biomarker of this condition. A retrospective chart review was performed collecting pre- and posttreatment data from GD patients. Eighteen patients with ferritin levels available before and after treatment were included in the study. Nine of these participants were males, and seventeen had type I GD. All patients were given either enzyme replacement (n = 16) or substrate reduction therapy (n = 2), and ferritin was found to decrease from 756 [318-1441] ng/mL at baseline to 521 [227-626] ng/mL (p = 0.025) after 28.8 months of treatment. Serum ferritin levels did not correlate with measures of disease severity, but showed an association with age at onset of treatment ( = 0.880; n = 18; p < 0.001). In conclusion, although serum ferritin did not correlate with disease severity, after a median 28.8 months of treatment, clinical outcomes had clearly improved, and ferritin levels had decreased.